Kinase inhibitors that target Bcr-Abl are highly effective in the treatment of chronic myeloid leukemia (CML). However, these inhibitors are often invalidated due to the drug resistance. Therefore, the discovery and development of novel Bcr-Abl inhibitors is required to overwhelm the drug resistance in the treatment of CML resistant to the currently used first-line Bcr-Abl inhibitors. Herein we have described a newly developed Bcr-Abl inhibitor CT-721, which displayed potent inhibitory effects on wild-type and T315I mutant Bcr-Abl. It functioned as a typically ATP-competitive inhibitor, superior to other existing Bcr-Abl inhibitors. CT-721 also demonstrated time-dependent inhibition of Bcr-Abl activation and the resultant downstream signaling transduction pathways in Bcr-Abl positive cells. Furthermore, CT-721 induced cell apoptosis and cell cycle arrest, and efficaciously inhibited tumor growth in Bcr-Abl-expressed K562 and KU812 xenograft models in a mechanism-based manner. Further PK/PD studies revealed a positive in vivo correlation between the compound concentration and inhibition of Bcr-Abl activity. Taken together, CT-721 is a potent and time-dependent Bcr-Abl kinase inhibitor, and has shown strong in vitro and in vivo anti-CML activities with a favorable pharmacokinetic profile, differentiating it from other Bcr-Abl kinase inhibitors already approved and current in development for the treatment of CML.
Introduction
Chronic myeloid leukemia (CML), a myeloproliferative disease, is characterized by the presence of a fused Bcr-Abl protein resulting from Philadelphia chromosome (a rearrangement between chromosome 9 and 22) [1, 2] . This fusion protein leads to the constitutive activation of Abl and downstream kinases on several signaling pathways, and consequently makes the cells escape from the normal regulation of cellular signaling possible. In the past two decades, studies showed that the fused Bcr-Abl protein was the main pathogenetic cause of CML, since the constitutive activation of Bcr-Abl played a critical role in cell transformation and leukemia oncogenesis [3] . The activation of multiple signaling pathways resulted in increased cell proliferation, reduced dependence on growth-factors, decreased apoptosis and accelerated cell division [4, 5] . Taken the in vitro and in vivo studies together, Bcr-Abl has been a new drug target for the treatment of CML.
Imatinib (Gleevec/STI-571) [6, 7] , a first-line clinical drug for CML patients based on its excellent efficacy and safety, is a small molecule Bcr-Abl inhibitor [7] . However, as the first generation Bcr-Abl inhibitor, imatinib was often invalidated due to the Ivyspring International Publisher development of cellular resistance to the drug during the treatment [8] . Now it has been demonstrated that the resistance is associated with Abl kinase mutations, especially T315I mutation in the gatekeeper region [9] . The second generation inhibitors, such as nilotinib [10] , dasatinib [11, 12] and bafetinib [13] , have been developed to overcome the imatinib resistance, and they are generally more potent and have achieved higher and faster responses than imatinib. Unfortunately, both T315I mutated Bcr-Abl and leukemia-initiating cells remained insensitive to them. Such a resistance occurs via several cell signaling pathways and/or is mediated by multiple protein kinases since the single T315I mutation in Bcr-Abl has accounted for only 15-20 % of the drug resistant cases [14, 15] . Therefore, tremendous efforts are being focused on development of the third-generation Bcr-Abl inhibitors targeting T315I mutation for the treatment of drug-resistant CML [16] . Some of those inhibitors, such as ponatinib/AP24534 [17] [18] [19] and DCC-2036 [20, 21] , have shown potent efficacy on the mutant resistance. In the current study, we reported an imidazopyridazine-based compound, CT-721, as a novel Bcr-Abl inhibitor based on computational modeling and Structure-Activity Relationship (SAR) analysis. CT-721 has a novel chemical structure with excellent inhibition on wild-type and T315 mutant Bcr-Abl kinase activity. We systemically studied the inhibitory mechanism and in vitro and in vivo efficacy of CT-721. Due to its excellent efficacy and favorable pharmacokinetic profile, CT-721 has been selected for further development for the treatment of Leukemia.
Materials and Methods

Compound synthesis
was designed and synthesized by Centaurus BioPharma Co., Ltd. Reference compound, Ponatinib
Compounds were stocked at 10 mM concentration in 100% DMSO and diluted for biological test prior to use in each experiment.
Cell culture
K562, KU812, Kasumi-1, MV-4-11, HL-60, Colo-205, A549 and MCF-7 cell lines were purchased from the cell bank of Chinese Academy of Science (Shanghai, China). MKN-45 human gastric carcinoma cell line was obtained from Health Science Research Resource Bank (Osaka, Japan). Ba/F3-Bcr-Abl WT/T315I stable cell line was generated as described [27, 28] .
Cells were cultured in DMEM or RPMI-1640 supplemented with 10% FBS, and 50 IU penicillin/streptomycin in a humidified atmosphere with 5% CO 2 at 37 ℃. Human PBMC cells were collected with Ficoll-Paque PREMIUM (GE Healthcare) according to manufacturer's guide. The medium, serum and antibiotics were purchased from Invitrogen.
Kinase enzyme assay
Abl, c-Kit, VEGFR2, PDGFRβ, c-Met, Alk enzymes were purchased from Millipore (Billerica, MA), and HTRF ® KinEASE TM -TK was obtained from Cisbio Bioassays. HTRF (Homogeneous Time-Resolved Fluorescence) assay was used to analyze kinase enzyme activity and compound potency. Compounds were serially diluted in 3 folds from 1 mM stock solution in DMSO for 11 points. 4 μL of the diluted solution of the compounds was added to 96 μL of reaction buffer (50 mM HEPES pH7.0, 0.1 mM Na3VO4, 0.01% BAS, 5 mM MgCl 2 , 1 mM DTT), then 2.5 μL of 4×compound solution and 5 μL of 2×kinase solution were added to a 384-well plate(OptiPlate-384, PerkinElmer). The resulted solutions were briefly mixed, centrifuged and incubated for 5min. Finally, 2.5 μL of 4×ATP/TK peptide (ATP at K m for each kinase) solution was added to the reaction system to initiate the reaction. The enzymatic reactions were carried out for 60-120 min at 23 o C, then terminated by adding 5 μL of detection solution containing TK antibody-cryptate and 5 μL of Streptravidin-XL-665. The mixtures were incubated for additional 1 hour at 23 o C. The fluorescent signals were read using EnVision multilable plate reader (PerkinElmer). IC 50 values of the compounds were generated using GraFit software (Version 6.0) and presented at the mean of three independent experiments performed in duplicate. The selective inhibition of CT-721 against site-mutated Abl variants E225K, G250E, Y253F, H369P, M351T and Q252H was performed by Thermo Fisher SCIENTIFIC with service of Broad Assay Panel.
Cell proliferation assay
The effects of CT-721 on cell proliferation were measured using Promega's kits (CellTiter-Glo ® or CellTiter-Blue ® Cell Viability Assay). Cells were seeded in 96-well plate at low destiny with 195 µL medium per well. The stock solutions of compounds in 100% DMSO were 3-fold serially diluted from 10 mM to 0.3 nM, and 4 µL of solution at each concentration was transfered to 96 µL of serum free medium (SFM), then 5 µL of the resulted solution was added to each well. After treatment for 72 hours, 25 or 35 µL of CellTiter-Glo ® (for adherent cells) or CellTiter-Blue ® (for suspension cells) reagent was added to each well, and the resulted mixture was further incubated at RT for 10 minutes or 4 hours. The luminescence/fluorescent signals were measured using EnVision ® multi-labelled plate reader (PerkinElmer) or FlexStation 3 (Molecular Devices) and IC 50 values were calculated using Prism ® software (Version 5.0) and reported at the average of three independent experiments performed in duplicate.
Western blot
K562 or KU812 cells were plated in 6-well plates at the density of 1x10 6 cells per well in 2 mL of the culture medium and cultured at 37 o C overnight under 5% CO 2 . The various concentrations of compound solutions were added to each well. Cells were collected and lysed after 60 minutes, and total protein concentrations were determined with a Bio-Rad BCA ® kit. Equal amounts of cell lysates were loaded onto 10% SDS gel and separated by electrophoresis. Separated proteins were then electro-transferred onto polyvinylidene fluoride (PVDF) membranes (Millipore, Bedford, MA). After being blocked with 1 X Tris-buffered saline (TBS) containing 0.1% Tween-20 and 5% bovine serum albumin (BSA), the membranes were incubated with primary antibodies at room temperature for 2 hours or at 4 o C O/N, then washed with 1X TBS containing 0.1% Tween-20 and followed by treatment with the horseradish peroxidase (HRP)-conjugated secondary antibody at room temperature for another 1 hour. The targeted proteins were visualized using an enhanced chemiluminescence (ECL) plus system (Thermo Fisher Scientific, Waltham, MA). Primary antibodies against phospho-Abl, phospho-Crkl, phospho-ERK, phospho-STAT3, phospho-STAT5, phospho-AKT, AKT and β-Actin and the horseradish peroxidase (HRP) conjugated goat anti-rabbit IgG were purchased from Cell Signaling Technology.
Flow cytometry
K562 cells were treated with 0.1 % DMSO (control) or with CT-721 solutions at indicated concentrations for 24 hours at 37 o C, then the cells were harvested by centrifugation and washed twice with PBS. Cell apoptosis was determined with a PE Annexin V Apoptosis Detection Kit (BD Biosciences, San Jose, CA) following the manufacture's guides. Breifly, cells were resuspended with 100 µL of binding buffer containing with Annexin V and 7-AAD. After 15 minutes incubation at room tempreture in the dark, 400 µL of binding buffer was added to the mixture and the cells were analyzed with a Guava flow cytometer (Millipore, Bedford, MA). Cell cycle arrest was evaluated by incorporation of propidium (PI) (Sigma-Aldrich, St.Louis, MO) into the permeablized cells. After being treated with DMSO or compounds for 24 hours, cells were harvested, washed twice with cold PBS, fixed with ice-cold 70% ethanol O/N followed by a secondary staining step with staining buffer (0.25 mg/mL Rnase, 0.025 mg/mL PI, in PBS) for 1 hour at 37 o C. Compound regulation of cell-cycle was analyzed using a Guava flow cytometer (Millipore, Bedford, MA). Data were analyzed with FlowJo software.
Tumor xenograft studies in nude mice
Female athymic nude mice (5-6 week) were used for all the in vivo studies. 5x10 6 cells in 100 µL of serum-free medium were planted subcutaneously on the right flank of mice. Tumor volumes were monitored by caliper measurement using the formula: tumor volume (mm 3 ) = (w 2 x l)/2, where w = width and l = length. When the tumor volumes reached 150~200 mm 3 , mice were randomized to groups (8-10 mice per group) and treated with compounds or vehicle by oral gavage every day for 2-4 weeks. The tumor volumes and body weight were measured every 2-3 days. Tumor growth inhibition (TGI) and body weight changes were calculated compared to the control groups. Statistical significance of the treatment groups compared to vehicle group was evaluated with t-test. All the experiments were carried out in accordance with the guidelines of institutional animal care and use committee (IACUC) of Centaurus BioPharma and approved by IACUC of Centaurus BioPharma.
Pharmacokinetic studies in rats
Female SD rats (5-6 week) were administrated with CT-721 at a single dose of 5 mg/kg and blood samples were taken sequentially from 2 minutes to 24 hours after compound administration. The serum samples were collected by centrifugation and stored at -80 o C. Compound concentrations in the sample serums were further analyzed by LC-MS/MS (API-4000, Applied Biosystem Inc.), and pharmacokinetic parameters (T 1/2 , T max , C max , AUC 0-INF ) were generated using WinNonlin software (WinNonlin Professional, version 6.2).
Results
CT-721 is a potent inhibitor of wild-type and T315I mutant Brc-Abl kinases
In an effort to develop T315I mutant Bcr-Abl sensitive inhibitor to overcome CML drug resistance, we had designed and synthesized CT-721 (Fig. 1a) , a novel small molecular inhibitor of wild-type and T315I mutant Bcr-Abl kinases. The efficacious inhibition of CT-721 on the Bcr-Abl kinase and T315I mutant Bcr-Abl kinase was similar to that of Ponatinib (data not shown) with IC 50 values of 21.3 ± 1.1 nM and 65.0 ± 6.2 nM, respectively (Fig. 1b) . Potent inhibition on other 6 imatinib-resistant mutants (E225K, G250E, Y253F, H369P, M351T and Q252H) was also observed. Furthermore, the selectivity of CT-721 was investigated by determining the inhibition profile over other human kinases involved in the progress of CML as well as AML, including c-Kit, VEGFRF2, PDGFRβ, EGFR, c-Met and Alk. As shown in Figure 1b , CT-721 also markedly inhibited c-Kit, VEGFR2, PDGFRβ and EGFR with IC50 values of 9.2 nM, 48.9 nM, 106 nM and 130 nM, respectively, implicating CT-721 could exert additional effects on CML other than targeting Bcr-Abl kinase. The kinetic experiments were performed to explore the inhibitory mechanism of CT-721 against Bcr-Abl. As shown in Fig. 1c , CT-721-mediated inhibition on Abl kinase activity can be significantly attenuated with increasing concentrations of ATP. Moreover, CT-721 had higher affinity to free Abl enzyme with a dissociation constant (Ki) value of 7.3 nM than that to the enzyme-ATP complex with a K i ' value of 775 nM. Lineweaver-Burk plots (Double-reciprocal plots) ( 
CT-721 has demonstrated time-dependent inhibition on Bcr-Abl kinase
In order to further characterize the inhibitory mechanism of CT-721 on Bcr-Abl, both biochemical assay and cellular assay were carried out. As shown in Fig. 2a , CT-721 demonstrated dose-dependent and time-dependent inhibitions on Bcr-Abl kinase activity in in vitro enzymatic studies. The IC50 value of CT-721 for Abl kinase was decreased by 9-fold from 12.1 nM to 1.3 nM after the kinase was pre-incubated with CT-721 for two hours, implicating that CT-721 inhibited Abl enzyme in a time-dependent manner (Fig. 2b) . In the further enzymatic kinetics study, CT-721 was characterized as a slow-and tight-binding inhibitor of Bcr-Abl kinase with Koff and EI t 1/2 values at 3.22 × 10 -3 min -1 and 216 minutes, respectively (Fig.  2c) . The main advantages of slow-and tight-binding inhibitors result from their high affinity and long residence time on their target enzymes due to the slow dissociation rates of typical tight binding inhibitors. Therefore, the slow-and tight-binding inhibitors usually lead to persistent and sustained inhibition of targeted enzyme activity. Indeed, the pre-treatment of K562 leukemia cells with 100 nM of CT-721 for one hour led to a persistent inhibition on phosphorylation of Bcr-Abl and its downstream targets, such as Crkl kinase and Stat3, up to at least 24 hours even after the compound was washed out (Fig.  2d) . Collectively, these results suggest that CT-721 is a time-dependent and slow-binding Abl kinase inhibitor.
CT-721 selectively inhibits proliferation of Bcr-Abl-expressing leukemia cells
The cell proliferation studies were executed to evaluate the inhibitory effects of CT-721 on several cell lines including solid tumor and leukemia cells abnormally expressing Bcr-abl or other oncogenic kinases. As shown in Table 1 Abl enzyme was pre-incubated with CT-721 at indicated concentrations for 0 min or 40 min, then inhibitory activities (IC50) was measured as described in Methods and Materials. (c) The inhibitory reversibility study of CT-721. Abl enzyme (100 nM, 100×) was pre-incubated with CT-721 (100 nM) for 2 hours, then the enzyme reaction was initiated by adding the substrates to a 100-fold diluted pre-incubation mixture. Enzyme rates in the presence of compound were determined at different times after a 100-fold dilution of pre-incubation mixture, and the rate of uninhibited reaction was normalized by using the enzyme activity in absence of compound as 100%. The kinetics parameter Koff and EI t1/2 was obtained from a one-phase exponential decay equation using the fitted data points. (d) Time-dependent and tight-binding characteristic of CT-721 inhibition on Abl mediated signal transduction. K562 cells were treated with 100 nM of CT-721 for 1 hour, then the medium containing compound was washed out and replaced with fresh medium for another 24 hours incubation (CT-721/0-24 h labeling in Figure 2d ), DMSO-untreated cells was used as control (control/0 h and control/24 h in Figure 2d ) . To investigate the underlying mechanisms of CT-721 inhibition on leukemia cells abnormally expressing Bcr-Abl, we evaluated the effects of CT-721 on cell signaling pathways that played important roles in proliferation of K562 and KU812 cells. CT-721 dose-dependently suppressed the phosphorylation of Bcr-Abl and its downstream protein Crkl in K562 and KU812 cell lines after these cells were treated with CT-721 for 1 hour (Fig. 3a and 3b) . CT-721 significantly suppressed phosphorylation of Bcr-Abl kinase at 10 nM, and totally blocked the phosphorylation at 100 nM. In the meantime, the phosphorylation of Crkl was also significantly inhibited by CT-721 at 100 nM. In the time course of inhibition studies, CT-721 demonstrated time-dependent inhibition on the phosphorylation of Bcr-Abl and Crkl in both K562 and KU812 cell lines ( Fig. 3c and 3d) . The phosphorylation of these proteins underwent substantial and sustained blockage up to at least 24 hours (Fig. 3c and 3d) . Multiple signal transduction pathways play key roles in Bcr-Abl mediated cell growth and tumorgenesis. The further studies showed that CT-721 only dose-dependently repressed the levels of phosphorylated ERK1/2 and STAT5 (Fig. 3a-3d) , and had no meaningful inhibition on the phosphorylation of STAT3 and AKT (data not shown). These results have mechanized that proliferation-associated MAPK and STAT5 signaling pathways are keys of CT-721 inhibition of the growth of K562 and KU812 cells.
CT-721 induces apoptosis and cell-cycle arrest in leukemia cells
Since CT-721 demonstrated significant inhibition on K562 cell growth, we further assessed its effects of on cell-cycle progression and apoptosis in K562 cells and Ba/F3-Bcr-Abl WT/T315I cells. CT-721 dose-dependently induced significant early-phase apoptosis in a dose-dependent manner after 24 hour treatment. Meanwhile, late-phase apoptosis was also observed in presence of 10 μM of CT-721 in the cells for 24 hours (Fig. 4a) . Similar results were obtained in Ba/F3-Bcr-Abl WT/T315I cells (data was not shown). These results supported that the observed anti-proliferation potency of CT-721 was correlated with its induction action of cell death. In the cell cycle analysis of K562 cells after cells were exposed to CT-721 for 24 hours (Fig. 5 ), CT-721 was able to induce pronounced G0/G1 phase arrest at 1 nM with a dose-dependent increase in the percentage of cells in G1 phase, and a decrease in the percentage of cells in S phase and G2/M phase (Fig. 5) . This was in agreement with the growth curves of K562 cells treated with CT-721, implicating that CT-721 suppressed the entrance of cells from G1 to S phase, interfered with the cell cycle progression and resulted in growth inhibition. Overall, there was a generally close agreement between CT-721-induced growth inhibition, apoptosis and cell-cycle arrest in Bcr-Abl-expressing cells.
Pharmacokinetics studies of CT-721 in SD rats
Since CT-721 showed excellent in vitro potency in enzymatic and cellular assays, we further evaluated its pharmacokinetics profile in SD rats. As shown in Table 2 , CT-721 was eliminated slowly in SD rats with a t 1/2 of 8.83 hours, but it was also absorbed slowly with a T max of 6.67 hours. CT-721 displayed high plasma exposures in rats with mean AUC at 5424 hr*ng/mL. In addition, CT-721 did not show significant inhibition on liver CYP450 enzymes (IC 50 greater than 10 μM for all tested enzymes, data not shown). PK parameters supported that CT-721 could be a strong candidate to move forward for further in vivo efficacy studies. 
CT-721 blocks tumor growth in K562 and KU812 xenograft mice
Due to its strong cell growth inhibition potency, we next performed a series of in vivo anti-cancer efficacy studies using xenograft mice bearing K562 and KU812 cells-derived tumors. In the K562 xenograft model, mice were orally administered with vehicle or CT-721 at 5, 15 or 45 mg/kg after tumors reached to 150-300 mm 3 . The results (Fig. 6a) showed that CT-721 suppressed K562 tumor growth in a dose-dependent manner and induced tumor regression at high dose of 45 mg/kg. After treated with CT-721 at 45 mg/kg for 9 days, 90% of mice were completely cured and the tumors disappeared completely (p < 0.01), and the others showed partial regression in this treatment group. In 15 mg/kg treatment group, CT-721 inhibited tumor growth significantly with 76% (p < 0.05) tumor growth inhibition after treatment for 12 days. In 5 mg/kg treatment group, the tumor growth inhibition was 51.4%, p < 0.05. Meanwhile, the body weights of xenograft mice were also monitored and CT-721 appeared to be well tolerated at all three doses without causing significant bodyweight loss (Fig. 6b) .
In another KU812 leukemia xenograft model, the anti-cancer efficacy of CT-721 was evaluated at the dosage of 30 mg/kg QD (Fig. 6c) . In the treatment group, tumor growth was notably inhibited with partial regression observed after 5 days. After 8 days, complete tumor regression was observed in 50% of treated mice (p < 0.01). After 18 days, 80% of treated mice showed completely tumor regression and the others showed partial tumor regression (p < 0.01). Similar to studies in K562 xenograft, no significant body weight loss was observed in all treatment objects compared to the vehicle group.
PK/PD studies in K562 xenograft model
To further explore the relationship between the in vivo anti-tumor growth efficacy and the inhibition on cell signal transduction of abnormal Bcr-Abl-expressing, pharmacokinetics (PK)/pharmacodynamics (PD) studies were performed in K562 xenograft model. The tumor tissues were harvested 2 hours after a single dose of CT-721 at 5 or 15 mg/kg. CT-721 exposures in tumor tissue and the phosphorylation levels of Bcr-Abl and its down-stream signal target ERK were analyzed. Bcr-Abl phosphorylation levels in CT-721 treated groups were significantly decreased in a dose-dependent way (Fig. 7a) . There existed well positively correlation between the concentration of CT-721 (Fig. 7b) and the inhibition of phosphorylation in both Bcr-Abl and ERK1/2 in tumor tissues. In the 15 mg/kg group, the compound concentration in tumor samples reached to 254 ng/mL, and almost complete inhibition of Bcr-Abl and ERK phosphrylation was observed. Collectively, these results have provided a direct relationship among compound exposures in tumor tissues, tumor growth inhibition, and the inhibition of phosphorylation of Bcr-Abl and its downstream targets. 
Discussion
The Bcr-Abl fusion protein, central to the pathogenesis of CML, interacts with a variety of effector proteins, leading to deregulated cellular proliferation, decreased adherence of leukemia cells to the bone marrow stroma, and a reduced apoptotic response to mutagenic stimuli [22] . Imatinib, a Bcr-Abl selective tyrosine kinase inhibitor, is highly effective in inducing durable remission, prolonging the survival of the majority of CML patients in the chronic phase and improving the outcome in Ph+ ALL patients. The judicious use of tyrosine kinase inhibitors targeting Bcr-Abl has become a proven strategy in treatment of CML for sustained control of disease progression [6, 23] . However, the inhibitor-induced resistance and relapse develops at high incidence rate owe to mutation in Bcr-Abl kinase domain [24, 25] . All of clinically proved Bcr-Abl inhibitors are unable to inhibit T315I mutated Bcr-Abl except ponatinib, which was limited to patients who were responsive to the drug and/or had the potential benefits outweighing the risks due to adverse events of life-threatening blood clots in arteries and veins according to FDA Drug Safety Communication. Therefore, there is a need for development of new agents that can effectively treat patients with T315I mutant. We here reported that CT-721, a novel small molecular inhibitor for Bcr-Abl kinase, was able to efficiently inhibit both wild-type and T315I mutant Bcr-Abl kinase with comparable potency to Ponatinib [18] , the most advanced Bcr-Abl inhibitor for leukemia treatment. More importantly, CT-721 has a more favorable PK and safety profile.
CT-721 was a potent ATP-competitive inhibitor against Bcr-Abl kinase, and it showed concentration-dependent and time-dependent inhibition on its target. In addition, CT-721 was demonstrated as a slow-and tight-binding inhibitor, which rendered it some main advantages, such as the high affinity to and the long residence time on its target. In agreement with its time-dependent and tight-binding characteristic, CT-721 showed persistent and sustained inhibition to Bcr-Abl phosphorylation and its downstream signaling molecules including Crk1 and Stat5 both in vitro and in vivo. CT-721 showed very potent and persistent inhibition on K562 and KU812 (highly-expressing Bcr-Abl fusion protein) leukemia cell growth with IC50 values around 1 nM, which was well associated with the time-and dose-dependent induction of cell apoptosis and cell cycle arrest. CT-721 sustainably prevented the phosphorylation of Bcr-Abl and its downstream protein Crk1 in a dose-dependent manner.
An important mechanism of drug resistance associated with tyrosine kinase inhibitors is the drugs-induced compensatory activation of cellular growth signal transduction pathways that bypass the inhibitory effects of drugs. Besides Bcr-Abl, CT-721 has demonstrated potent inhibition of other tyrosine kinases such as VEGFR2, PDGFRβ, which are equally important players in hematological malignancies and the potential bypass pathways for drug resistance. CT-721 also efficaciously blocked the phosphorylation of STAT5 and MAPK in K562 and KU812 cells. Overall, our studies have strongly indicated that CT-721 suppressed cell growth possibly through targeting Bcr-Abl and cross-talking of several Bcr-Abl-associated signaling pathways. Pharmacokinetic studies demonstrated that CT-721 was metabolized slowly and had better oral exposures than Ponatinib [26] . CT-721 did not show significant inhibitory effect against liver CYP450 enzymes (IC50 > 10 μM, data not shown). In K562 and KU812 xenograft models, CT-721 was able to induce tumor regression, manifesting excellent tumor growth inhibition. The further in vivo PK/PD studies demonstrated that the inhibition of Bcr-Abl and ERK phosphorylation in xenograft tumors by CT-721 was well correlated with its concentrations in tumor tissues, indicating that the in vivo blockage of tumor growth by CT-721 was mechanism-based.
In conclusion, our studies showed that CT-721 was a potent and time-dependent inhibitor of wild-type and T315I mutant Brc-Abl kinases, induced apoptosis and suppressed tumor growth of leukemia cells harboring Bcr-Abl fusion. Moreover, CT-721 showed the long-acting efficacy in in vitro and in vivo studies.
In particular, CT-721 had better pharmacokinetics parameters and toxicity profile than Ponatinib, thus it should be much better than Ponatinib in safety profile. Therefore, CT-721 has a potential application for treatment of CML as a best-in-class candidate.
